Table I.
Number of mice vaccinated with RBD-rAAV (RBD) or blank AAV (AAV)a
| Vaccinations | Total (n) |
Humoral IR (n) |
Local IR (n) |
CTL IR (n) |
SARS-CoV (#) |
||
|---|---|---|---|---|---|---|---|
| Young | Aged | ||||||
| RBD | |||||||
| im.P | 28 | 5 | 4 | 5 | 4 | 5 | |
| im.B | 28 | 5 | 4 | 5 | 4 | 5 | |
| in.P | 14 | 5 | 4 | 5 | |||
| in.B | 62 | 5 | 4 + 39 | 5 | 4 | 5 | |
| AAV | |||||||
| im.B | 28 | 5 | 4 | 5 | 4 | 5 | |
| in.B | 62 | 5 | 4 + 39 | 5 | 4 | 5 | |
a
Five mice per group were monitored for systemic humoral immune response (IR; serum IgG and NA). Four mice per group were tested for local IR (lung flush IgA). Mice with i.n. prime-boost vaccination of RBD-rAAV or blank AAV (in.B, 39 mice/group) were used for detection of lung flush IgA and NA at different time points at 0.5-mo intervals for up to 6 mo, and three mice for each group were tested at each time point. n, The number of mice and SARS-CoV means challenged with SARS-CoV. im.P, in.P, and im.B indicate i.m. or i.n. immunized with a single prime dose, or i.m. prime-boost doses of RBD-rAAV or blank AAV, respectively.